Corline Biomedical: Our view on the phase I data

Redeye reiterate its positive stance towards Corline following the release of Phase I data with its lead candidate Renaparin. As stated in our initiation report, we saw good prospects of a positive outcome and assigned the trial a probability of success of 85%. With today’s encouraging safety data, we now consider the asset Phase II-ready and raise of our Base case to SEK 35 (30)..